PREVYMIS 240 mg concentrate for solution for infusion

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

1. What PREVYMIS is and what it is used for
2. What you need to know before you are given PREVYMIS
3. How you are given PREVYMIS
4. Possible side effects
5. How to store PREVYMIS
6. Contents of the pack and other information

• you are allergic to letermovir or any of the other ingredients of this medicine (listed in section 6).
• you take either of these medicines:
  • pimozide - used for Tourette’s syndrome
  • ergot alkaloids (such as ergotamine and dihydroergotamine) - used for migraine headaches.
• you take the following herbal product:
  • St. John’s wort (Hypericum perforatum)

You should not be given PREVYMIS if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before you are given PREVYMIS.

• dabigatran - used for blood clots
• atorvastatin, simvastatin, rosuvastatin, pitavastatin - for high cholesterol.

If you are also taking a medicine for high cholesterol (see list of medicines in section “Other medicines and PREVYMIS” below) you must tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Your medicine or dose may then need to be changed. See the package leaflet for your other medicine for further information.

Additional blood tests may be needed to monitor the following medicinal products:

• Ciclosporin, tacrolimus, sirolimus
• Voriconazole

PREVYMIS is not for use in children and adolescents under 18 years old. This is because PREVYMIS has not been tested in this age group.

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because PREVYMIS may affect the way other medicines work, and other medicines may affect how PREVYMIS works. Your doctor or pharmacist will tell you if it is safe to take PREVYMIS with other medicines.

There are some medicines you must not take with PREVYMIS (see list under “You should not be given PREVYMIS if:”).

There are some additional medicines you must not take with PREVYMIS and ciclosporin (see list under “If you are taking PREVYMIS with ciclosporin, do not take the following medicines:”).

Also tell your doctor if you are taking any of the following medicines. This is because your doctor may have to change your medicines or change the dose of your medicines:

• alfentanil - for severe pain
• fentanyl - for severe pain
• quinidine - for abnormal heart rhythms
• ciclosporin, tacrolimus, sirolimus - used to prevent transplant rejection
• voriconazole - for fungal infections
• statins, such as atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin - for high cholesterol
• glyburide, repaglinide - for high blood sugar
• carbamazepine, phenobarbital, phenytoin - for fits or seizures
• dabigatran, warfarin - used to thin the blood or for blood clots
• midazolam - used as a sedative
• amiodarone - used to correct irregular heartbeats
• oral contraceptive steroids - for birth control
• omeprazole, pantoprazole - for stomach ulcers and other stomach problems
• nafcillin - for bacterial infections
• rifabutin, rifampicin - for mycobacterial infections
• thioridazine - for psychiatric disorders
• bosentan - for high blood pressure in the vessels in the lungs
• efavirenz, etravirine, nevirapine, lopinavir, ritonavir - for HIV
• modafinil - for wakefulness

You can ask your doctor or pharmacist for a list of medicines that may interact with PREVYMIS.

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. PREVYMIS is not recommended in pregnancy. This is because it has not been studied in pregnancy and it is not known if PREVYMIS will harm your baby while you are pregnant.

If you are breast-feeding or are planning to breast-feed, tell your doctor before taking this medicine. Breast-feeding is not recommended while taking PREVYMIS. This is because it is not known if PREVYMIS gets in your breast milk and will be passed to your baby.

PREVYMIS may have minor influence on your ability to drive and use machines (see section 4 Possible side effects below). Some patients have reported fatigue (feeling very tired) or vertigo (feeling like you are spinning) during treatment with PREVYMIS. If you experience any of these effects, do not drive or use machines until the effect wears off.

PREVYMIS contains sodium. If you are on a low sodium diet, talk to your doctor before you are given this medicine.

Each 240 mg vial contains 23 mg sodium (main component of cooking/table salt). This is equivalent to 1.15% of the recommended maximum daily dietary intake of sodium for an adult.

Each 240 mg (12 mL vial) of this medicine contains 1800 mg cyclodextrin.

If you have a kidney disease, talk to your doctor before you receive this medicine.

If you think you have been given too much PREVYMIS, tell your doctor straight away.

It is very important that you do not miss or skip doses of PREVYMIS.

• If you miss your appointment to get PREVYMIS, call your doctor straight away to reschedule your appointment.

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

The active substance is letermovir. Each vial contains 240 mg letermovir. Each mL of concentrate contains 20 mg.

The other ingredients are: hydroxypropylbetadex (cyclodextrin), sodium chloride, sodium hydroxide (E524), water for injections.

PREVYMIS 240 mg concentrate for solution for infusion is a clear, colourless liquid and may contain a few product-related small translucent or white particles.

The 240 mg concentrate for solution for infusion is packaged in clear, glass vials. Each vial is packaged in a carton.

Marketing Authorisation Holder:

Manufacturer:

For any information about this medicine, please contact: